Skip Navigation
Skip to contents

JYMS : Journal of Yeungnam Medical Science

Indexed in: ESCI, Scopus, PubMed,
PubMed Central, CAS, DOAJ, KCI
FREE article processing charge
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
1 "Chromogranin A"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original article
Prognostic impact of chromogranin A in patients with acute heart failure
Hong Nyun Kim, Dong Heon Yang, Bo Eun Park, Yoon Jung Park, Hyeon Jeong Kim, Se Yong Jang, Myung Hwan Bae, Jang Hoon Lee, Hun Sik Park, Yongkeun Cho, Shung Chull Chae
Yeungnam Univ J Med. 2021;38(4):337-343.   Published online July 8, 2021
DOI: https://doi.org/10.12701/yujm.2020.00843
  • 4,000 View
  • 76 Download
  • 2 Crossref
AbstractAbstract PDFSupplementary Material
Background
Chromogranin A (CgA) levels have been reported to predict mortality in patients with heart failure. However, information on the prognostic value and clinical availability of CgA is limited. We compared the prognostic value of CgA to that of previously proven natriuretic peptide biomarkers in patients with acute heart failure.
Methods
We retrospectively evaluated 272 patients (mean age, 68.5±15.6 years; 62.9% male) who underwent CgA test in the acute stage of heart failure hospitalization between June 2017 and June 2018. The median follow-up period was 348 days. Prognosis was assessed using the composite events of 1-year death and heart failure hospitalization.
Results
In-hospital mortality rate during index admission was 7.0% (n=19). During the 1-year follow-up, a composite event rate was observed in 12.1% (n=33) of the patients. The areas under the receiver-operating characteristic curves for predicting 1-year adverse events were 0.737 and 0.697 for N-terminal pro-B-type natriuretic peptide (NT-proBNP) and CgA, respectively. During follow-up, patients with high CgA levels (>158 pmol/L) had worse outcomes than those with low CgA levels (≤158 pmol/L) (85.2% vs. 58.6%, p<0.001). When stratifying the patients into four subgroups based on CgA and NT-proBNP levels, patients with high NT-proBNP and high CgA had the worst outcome. CgA had an incremental prognostic value when added to the combination of NT-proBNP and clinically relevant risk factors.
Conclusion
The prognostic power of CgA was comparable to that of NT-proBNP in patients with acute heart failure. The combination of CgA and NT-proBNP can improve prognosis prediction in these patients.

Citations

Citations to this article as recorded by  
  • The Role of Congestion Biomarkers in Heart Failure with Reduced Ejection Fraction
    Michele Correale, Francesco Fioretti, Lucia Tricarico, Francesca Croella, Natale Daniele Brunetti, Riccardo M. Inciardi, Anna Vittoria Mattioli, Savina Nodari
    Journal of Clinical Medicine.2023; 12(11): 3834.     CrossRef
  • Novel Biomarkers of Renal Dysfunction and Congestion in Heart Failure
    Agata Zdanowicz, Szymon Urban, Barbara Ponikowska, Gracjan Iwanek, Robert Zymliński, Piotr Ponikowski, Jan Biegus
    Journal of Personalized Medicine.2022; 12(6): 898.     CrossRef

JYMS : Journal of Yeungnam Medical Science